Biotechnology company specializing of psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders Nova Mentis Life Science Corp. (CSE: NOV) (OTCQB: NMLSF) has submitted a provisional patent application with the United States Patent and Trademark Office (USPTO) for proprietary manufacturing process for production of aeruginascin, tryptamine analogues, baeocystin and psilocybin.
The above compounds are active compound in magic mushrooms that even when administered at a low dose can produce psychoactive effects. The levels of these compounds in dried mushrooms range between 0.2% to 1% of their dry weight.
The proprietary manufacturing process of producing these compounds is owned by Nova Mentis this patent application will enable the company to have a total control in the future as it moves on to test these compounds under U.S. FDA approved guidelines for clinical studies.
“NOVA is developing a novel, proprietary synthetic drug pipeline, and our provisional U.S. patent application is an important step forward on our pathway to U.S. FDA drug approval and commercialization. We’re proud and excited about the technology NOVA has developed in conjunction with our API manufacturing partner and believe we have a great opportunity to demonstrate how our psilocybin-based therapeutics can help treat chronic neuroinflammatory disorders, including autism spectrum disorder (ASD),” said the company’s CEO, Will Rascan.
